Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs STMicroelectronics NV — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.53 (market cap $12.58B), while STMicroelectronics NV trades at $51.9 (market cap $48.14B). The key difference: STMicroelectronics NV is far larger — about 3.8× Halozyme Therapeutics Inc. Common Stock's market cap, and STMicroelectronics NV pays a 0.68% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and STMicroelectronics NV for 66 Days on average.
| HALO | STM | |
|---|---|---|
Market Cap | $12.58B | $48.14B |
Volume | 2,179,278 | 9,776,015 |
Sector | Health | Technology |
52-Week High | $115.22 | $79.91 |
52-Week Low | $61.63 | $21.20 |
Typical Hold Time | 1 Days | 66 Days |
Enterprise Value | $14.49B | $45.66B |
Dividend Yield | — | 0.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
STM (STMicroelectronics) trades at $51.88, down 7.65% on the day, amid a bearish technical signal. The stock shows mixed fundamentals with a high P/E of 101.49 and negative net income margin of -0.39%, though Q2 2026 EPS beat expectations. Recent news highlights recovery in automotive and industrial demand, with AI data-center revenue projected to exceed $2 billion by 2027. Cash flow improved in 2025 with net cash flow of $555 million, while the balance sheet remains solid with total assets of $24.74 billion.
The outlook is cautiously optimistic given analyst consensus favoring Buy ratings (51.72%) and a $77.31 price target, implying significant upside. Key risks include earnings volatility, competitive pressures in semiconductors, and macroeconomic headwinds. Near-term performance hinges on execution of AI and automotive growth initiatives, with Q3 2026 earnings as a critical catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
